Celemics

Celemics was founded in 2010 and listed on KOSDAQ in August 2020 under the technology-growth special listing track as a genomic analysis technology platform company.

Built on its proprietary cloning technology (MSSIC), the company provides target-capture kits for next-generation sequencing (NGS), sequencing analysis services (BTSeq), and immune-repertoire analysis solutions.

Only a small number of companies worldwide have commercialized target-capture kits, and Celemics is known as one of the few holders of high-quality NGS panel synthesis technology in Asia and Europe.

In terms of revenue mix, sales of genetic mutation detection kits for hereditary diseases and solid tumors account for roughly 65% of revenue, with the remainder coming from analysis services on the resulting genetic data; both segments are reported to be weighted toward overseas sales.

Its customer base includes biopharma companies, CROs, and drug-discovery research institutions, and recent overseas wins have been reported, including an eye research institute at Oakland University in the United States switching from a competitor's panel to Celemics' product.

The company holds five products registered as FDA Class 1 medical devices and has a supply track record with Korea's disease control agency. More recently, Celemics has been pushing into new businesses such as NGS-based MRD (minimal residual disease) kits, aiming to expand into precision medicine and liquid biopsy.

The competitive landscape is split between large global sequencing equipment and reagent makers and a small group of specialized target-capture kit providers, with entry barriers reportedly tied to long development timelines and accumulated technical know-how.

Annual revenue contracted over multiple years, from KRW 8.73bn in 2022 to KRW 6.58bn in 2023, KRW 6.72bn in 2024, and KRW 5.77bn in 2025. Operating losses were KRW 5.73bn in 2022 and KRW 5.77bn in 2023, narrowed temporarily to KRW 1.90bn in 2024, then widened again to KRW 3.32bn in 2025.

On the net income line, controlling-interest net income swung to a large positive KRW 12.27bn in 2024, a result that appears driven by factors separate from underlying operating improvement, before reverting to a controlling-interest net loss of KRW 4.04bn in 2025.

On a quarterly basis, the company posted a controlling-interest net profit of KRW 1.93bn in 3Q25, even as operating losses persisted across four consecutive quarters (2Q25: -KRW 1.34bn, 3Q25: -KRW 1.08bn, 4Q25: -KRW 0.46bn, 1Q26: -KRW 1.43bn, 2Q26: -KRW 0.92bn), suggesting a one-off factor distinct from core operating performance.

Notably, in 1Q26 and 2Q26 revenue came in at only KRW 0.92bn and KRW 1.38bn respectively, below the prior-year quarters, while net losses expanded to KRW 6.05bn and KRW 5.23bn, far exceeding the corresponding operating losses of KRW 1.43bn and KRW 0.92bn—indicating non-operating items such as derivative valuation losses tied to convertible bonds or capital raises likely had a significant impact on net results.

Controlling-interest equity rose from KRW 15.88bn in 2023 to KRW 27.18bn in 2024 before declining to KRW 23.02bn in 2025, and operating cash flow was negative for four straight years from 2022 through 2025 (-KRW 4.15bn, -KRW 4.53bn, -KRW 0.38bn, -KRW 3.60bn), reflecting a persistent cash drain from core operations.

The NGS (next-generation sequencing) industry is generally understood to be expanding its range of applications—diagnostics, drug discovery, microbiome, and seed development—amid falling sequencing costs and the spread of precision medicine.

Companies that have commercialized target-capture kits are few worldwide, making it a niche market with high entry barriers, but large sequencing equipment and reagent makers hold considerable influence, which can limit the bargaining power of smaller technology firms.

Within Korea's bio/healthcare sector, reports point to a clear divergence between companies showing confirmed earnings improvement (such as medical device makers in areas like vascular catheters) and those with persistent earnings weakness.

Celemics is seeking to broaden its application scope through precision-medicine initiatives such as liquid-biopsy-based early cancer detection and MRD kits, but its specific market share or competitive standing in these areas is not yet supported by disclosed financial results.

Infectious-disease events, such as recent hantavirus cases on a cruise ship, have at times drawn market attention to the company as a holder of related diagnostic panel technology, though whether such thematic interest translates into sustained revenue remains to be confirmed.

The coexistence of a structurally growing end market with the company's own revenue contraction is a point warranting attention when assessing this stock.

In February 2026, the company raised roughly KRW 19.0bn through a KRW 4.3bn third-party private placement and a KRW 5.0bn convertible bond issuance, and its new CEO stated a policy of strengthening strategic collaborations with large domestic and overseas corporations and quickly establishing new cash-generating businesses.

Subsequently, in April-May 2026, SuAhn Financial Investment invested KRW 8.55bn through a convertible bond, reportedly with an earn-out clause under which management control could transfer depending on future performance.

Industry sources in the investment banking sector view this financing as potentially laying the groundwork for a future change of control, though this has not been finalized.

The company is pursuing new businesses such as NGS-based MRD kits and reportedly expects rising demand from the industrialization of precision medicine and the expansion of liquid-biopsy-based early cancer detection markets.

However, as of 1Q26, declining sales of core products such as Target Capture Kits and BTSeq Kits were cited as the main drivers of deteriorating gross profit and operating income, making the pace at which new businesses convert to revenue—enough to offset core business weakness—a key point to watch.

An investment banking source noted that expanding overseas sales in the second half and translating that into earnings improvement will be the deciding factor. How efficiently the raised capital is deployed and how quickly new businesses convert to actual sales in coming quarters are the central items to monitor.